By Attending This Course, You WillKnow what determines the value of life science biotechs and emerging pharma companies.Gain a thorough understanding of key valuation terms, concepts, tools & techniques.Be able to assess the risk profile of a biotech company prior to its valuation.Learn and practice how to calculate the value of a biotech company.Learn and practice how to calculate the value of a development compound (using an Excel tool you can take home and use for any other compound in development).Know how to structure licensing deals between pharma and biotech, covering issues such as milestones and royalty payments.Why You Should AttendValuation is an inherently subjective task which is made even more difficult in the life science industry due its unique challenges: high attrition rates in R&D, long investment cycle, complex technologies and IP situations, etc. Therefore, traditional valuation methods are not suitable.The Content: This course is designed to teach you a systematic approach to producing a valuation which can be used in investment rounds, mergers/acquisitions, licensing deals or strategic development decisions in the pharma-biotech world. It goes beyond the number-crunching techniques of most consultants and includes difficult to define qualitative factors which shape the risk profile of the company in question.The Expert: Patrik Frei is a leading expert in the valuation of life science companies and his combination of knowledge and experience allows him to speak with authority on the subject. Patrik wrote the first book on the valuation of high-growth companies and holds a Ph.D in the field. His company, Venture Valuation, has completed over 400 independent company and product valuations.The Pharma-Biotech Product & Company Valuation  - An Introductory Course is the only available public training course delivered by Patrik Frei on the topic of Valuation.